DLL4 and breast carcinoma: Since DLL4 could be adaptively upregulated by docetaxel, thus attenuating the cytotoxic effects of this agent [474], the addition of an anti-DLL4 monoclonal antibody, MMGZ01, reasonably enhanced this taxane efficacy in breast cancer xenografts through depleting the subpopulation of CSC, reversing the EMT, and inhibiting the formation of functional tumor vessels [475].